Aurinia (AUPH): Generic Delay Until 2036 Leaves Runway Incomplete

[INDEX: 1.1.1]

On August 19, 2026, Aurinia Pharmaceuticals (AUPH) settled its U.S. LUPKYNIS patent litigation with generic-drug maker Teva, delaying Teva’s potential launch until December 7, 2036, subject to standard contingencies and regulatory approvals. That marks concrete legal progress for Aurinia’s sole commercial franchise, but leaves the operational runway incomplete: patent actions against five other generic applicants remain active, reported earnings rely heavily on accounting accruals, and forward earnings are expected to contract.

Per StockLens’s model, as of August 21, 2026, Aurinia receives a Composite score of 83 and a Solid rating. That summary balances considerable balance-sheet and operating capacity against weak cash conversion.

Teva Settlement Leaves Five Competitors Active in Court

Teva stipulated that Aurinia’s relevant patents, expiring in December 2037, are valid and enforceable, and that its proposed generic product would infringe them. In return, Aurinia granted Teva a U.S. commercial license effective on the agreed December 2036 date. However, that timeline remains subject to standard legal contingencies that could permit earlier market entry, as well as regulatory clearance.

Crucially, separate patent cases remain active against DifGen, Dr. Reddy’s and Galenicum, Hikma, Lotus and Sandoz, and Zydus. The Teva settlement removes one challenger from court; it establishes no binding precedent for the rest of the generic field.

Strong Capacity Meets Weak Earnings Conversion

Within the Healthcare sector, Aurinia’s Profitability score of 91 and Financial Health score of 91 signal ample operating and balance-sheet capacity to fund LUPKYNIS commercialization, ongoing patent defense, and pipeline development. The primary counterweight is an Efficiency score of 28, which sharply decouples from those headline capacity readings.

The Sloan Ratio stands at 0.22 against a peer median of -0.05, and its deteriorating trajectory shows that reported accounting profits outrun actual operating cash generation. Furthermore, current profitability is not projected to persist: Forward EPS Growth (Est.) points to an expected 66.9% decline over the coming year. These factors qualify the commercial certainty created by the settlement, as legal clarity around one applicant coexists with weak cash conversion and anticipated earnings normalization.